"80 Goodmans lawyers ranked as top-tier in 31 areas of law." - Canadian Legal Lexpert Directory
Goodmans Deals & Cases

This section contains brief summaries of selected significant cases and transactions.  You'll also find representative lists  - by year - of major transactions and cases where Goodmans' involvement is a matter of public record or where inclusion in the list has been authorized by our clients.

Sunovion Pharmaceuticals Acquires Cynapsus Therapeutics for $841 Million

2016

Areas Competition, Antitrust and Foreign Investment, Corporate and Commercial, Employment and Labour, Health Care Law, Intellectual Property , Litigation, Pensions, Tax

Summary

Goodmans represented Suovian Pharmaceuticals Inc. (Sunovion) in connection with its acquisition by plan of arrangement of Cynapsus Therapeutics Inc. (Cynapsus) (NASDAQ: CYNA) (TSX: CTH)  for approximately $841 million.  The acquisition is aligned with Sunovion’s global strategy to expand and diversify its portfolio in key therapeutic areas, including neurology. 

Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions.  Sunovion is headquartered in Marlborough, Massachusetts and is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., a leading Japanese pharmaceutical company.

Cynapsus is a specialty central nervous system pharmaceutical company based in Toronto that has been developing a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson's Disease.